Warnex

Warnex is a Canadian biotechnology company listed on the Toronto Stock Exchange (TSX WNX). The company is devoted to protecting public health by providing advanced diagnostic products and science-based services to the agri-food, pharmaceutical and healthcare sectors.

This two-pronged approach enables Warnex to generate a solid base of service-driven revenue, while benefiting from the high growth opportunity deriving from its promising pathogen detection technology.

The specialized laboratory services offered at Warnex includes the following services.

• Warnex Analytical Services provides traditional chemistry, microbiology, chromatography and stability testing, as well as method development and validation, to clients in the pharmaceutical and biotechnology industries.
• Warnex Bioanalytical Services conducts bioavailability and bioequivalence studies for clinical trials, and performs contract R&D for clients in the pharmaceutical and biotechnology industries. 
• Warnex Medical Laboratories provides specialized medical laboratory testing, including the Prenatest® prenatal screening test for Down syndrome (trisomy 21), trisomy 18 and other chromosomal anomalies.

The Warnex™ Rapid Pathogen Detection System assesses the presence of pathogenic contamination of a food product by specifically identifying the DNA signature of a pathogen. As the DNA signature of each pathogen is unique, this identification is highly specific and accurate. The system allows for the simultaneous detection of multiple pathogens and processing of samples within 3 to 48 hours, a significant improvement over traditional microbiology tests that currently require 5 to 7 days.

SGF participation: 25%

www.warnex.ca